Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia | Zendy

Robert W. Buchanan | Zendy; Robert Freedman | Zendy; Daniel C. Javitt | Zendy; Anissa AbiDargham | Zendy; J.A. Lieberman | Zendy

Open Access

Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia

Author(s) -

Robert W. Buchanan,

Robert Freedman,

Daniel C. Javitt,

Anissa AbiDargham,

J.A. Lieberman

Publication year - 2007

Publication title -

schizophrenia bulletin

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.823

H-Index - 190

eISSN - 1745-1707

pISSN - 0586-7614

DOI - 10.1093/schbul/sbm083

Subject(s) - neurocognitive , schizophrenia (object oriented programming) , cognition , context (archaeology) , psychology , schizophrenia research , neuroscience , psychiatry , psychotherapist , medicine , paleontology , biology

Wayne Fenton was a major driving force behind the establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project mechanisms. These projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified 3 drug mechanisms of particular interest: cholinergic, dopaminergic, and glutamatergic. The TURNS project is designed to select potential cognitive-enhancing agents and evaluate their potential efficacy in the context of proof of concept or clinical efficacy trials. This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research